Cerqueira Brenda Brenner S, Lasham Annette, Shelling Andrew N, Al-Kassas Raida
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):140-51. doi: 10.1016/j.ejpb.2015.10.007. Epub 2015 Oct 26.
It is anticipated that by 2030 approximately 13 million people will die of cancer. Common cancer therapy often fails due to the development of multidrug resistance (MDR), resulting in high morbidity and poor patient prognosis. Nanotechnology seeks to use drug delivery vehicles of 1-100 nm in diameter, made up of several different materials to deliver anti-cancer drugs selectively to cancer cells and potentially overcome MDR. Several technologies exist for manufacturing and functionalizing nanoparticles. When functionalized appropriately, nanoparticles have been shown to overcome several mechanisms of MDR in vivo and in vitro, reduce drug side effects and represent a promising new area of anti-cancer therapy. This review discusses the fundamental concepts of enhanced permeability and retention (EPR) effect and explores the mechanisms proposed to enhance preferential "retention" in the tumour. The overall objective of this review was to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancer.
预计到2030年,约1300万人将死于癌症。常见的癌症治疗常常因多药耐药性(MDR)的产生而失败,导致高发病率和患者预后不良。纳米技术试图使用由几种不同材料组成的直径为1至100纳米的药物递送载体,将抗癌药物选择性地递送至癌细胞,并有可能克服多药耐药性。存在多种用于制造纳米颗粒并使其功能化的技术。当进行适当的功能化时,纳米颗粒已被证明能在体内和体外克服多种多药耐药机制,减少药物副作用,代表了一个有前景的抗癌治疗新领域。本综述讨论了增强渗透与滞留(EPR)效应的基本概念,并探讨了为增强在肿瘤中的优先“滞留”而提出的机制。本综述的总体目标是增进我们对用于癌症治疗的治疗性纳米颗粒设计与开发的理解。